|
Purpose : Purpose:
To compare the effect of bimatoprost 0.01% monotherapy in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) who have switched from other prostaglandin analogue (PGA) or prostamide treatments.
Methods : Methods:
In this prospective, multi-centered, open-label, longitudinal study, hyperemia was measured at week 12 by a masked evaluator using a photonumeric grading scale (0, +0.5, +1, +2, +3). Hyperemia was grouped as (0 to +1) and (+2 to +3). Shifts between groupings were reported as no change, improved (+2 to +3) to (0 to +1) or worsened (0 to +1) to (+2 to +3). Mean change in IOP was measured at week 12.
Results : Results:
A total of 248 OAG or OHT patients were switched from another IOP lowering treatment to bimatoprost 0.01% and observed for 12 weeks. Of these, there were 125 (50.4%) who switched from another PGA or prostamide. Patients who switched from latanoprost 0.005% were (N=73; 58.4%), tafluprost 0.0015% (N=24; 19.2%), travoprost 0.004% (N=21; 16.8%) and bimatoprost 0.03% (N=7; 5.6%). Mean IOP baseline values for latanoprost 0.005%, tafluprost 0.0015%, travoprost 0.004% and bimatoprost 0.03%, were 16.3 ± 3.9 mmHg, 17.2 ± 3.8 mmHg, 18.2 ± 5.7 mmHg and 12.1 ± 2.7 mmHg, respectively. Mean IOP change at week 12 from baseline in latanoprost 0.005% were -2.2 mmHg (p<0.05); tafluprost 0.0015% -2.5 mmHg (p<0.05); travoprost 0.004% -4.2 mmHg (p<0.05) and bimatoprost 0.03% -1.7 mmHg (p=not estimable). At week 12, hyperemia shifts reported as improved, no change and worsened, respectively with latanoprost 0.005% were 0.0%, 98.0% and 2%; 0.0%, 87.0% and 13.0% with tafluprost 0.0015%; 23.1%, 76.9% and 0.0% with travoprost 0.004% and 0.0%, 100.0% and 0.0% with bimatoprost 0.03%.
Conclusion : Conclusion:
Subjects who switched to bimatoprost 0.01% monotherapy from a previous prostaglandin analogue had minimal changes in hyperemia from baseline with significant additional IOP lowering.
|